The Europe Antibiotics Market would witness market growth of 4.9% CAGR during the forecast period (2020-2026).
The rising case of bloodstream infections, pneumonia, and Urinary Tract Infections (UTI) is expected to boost the usage of carbapenems class of antibiotics. The increasing threat of drug-resistance is the key factor for the development of advanced combinational formulations. For example, the advent of multi-resistance tuberculosis and infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) is hard to cure with antibiotics, thus, the development of advanced antibiotics is needed.
Moreover, favorable government regulations like the Generating Antibiotics Incentives Now (GAIN) Act are estimated to speed up the approval process. GAIN Act has some provisions that help in the development of therapies against antibiotic-resistant pathogens. The major cause of death among children around the world is Diarrhea and it needs antibiotic intervention to stop the morbidity. Some other infectious diseases that created a high burden are pneumonia, HIV/AIDS, tuberculosis, and malaria. Apart from that, the birth of new infections, like the Zika and Ebola virus, are also assisting in the development and uptake of antibiotics.
The rising numbers of patients who are suffering from infectious diseases lead to the growth of the antibiotics market. Many pharmaceuticals companies are conducting on-going trials that are likely to propel the growth of the market. Additionally, advancement in antibiotics drugs and novel combination therapies to cure antibiotic-resistant microbial infections will improve the treatment scope, thereby driving the growth of the antibiotic market during the forecast period. Moreover, the special designation from the regulatory authority to several capable pharmaceutical companies, is the factor that further boosts the market growth.
Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
Scope of the Study
Market Segments covered in the Report:
By Action Mechanism
• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors,
• Mycolic Acid Inhibitors
By Drug Class
• Rest of Europe
• GlaxoSmithKline PLC (GSK)
• Johnson and Johnson
• Merck & Co., Inc.
• Pfizer, Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
Executive Summary The Global Peptide Therapeutics Market is valued at USD 32.1 Billion in the year 2020. The growth of Peptide Therapeutics is directly associated with drug development. New drug discovery and product launch in chronic metabolic disorders would provide fruitful opportunities for Peptide Therapeutics Market....
Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective This report provides you with a landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technology...
The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4billion in 2021, at a CAGR of 31.4%. Growth in this market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in...
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 184.108.40.206) - Drugs In Development, 2021 Summary Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 220.127.116.11) - Frataxin is a protein encoded by the FXN gene. It promotes the biosynthesis of heme and assembly and repair of iron-sulfur...
Aryl Hydrocarbon Receptor - Drugs In Development, 2021 Summary According to the recently published report ’Aryl Hydrocarbon Receptor - Drugs In Development, 2021’; Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 29 molecules....
“Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the...
The global injectables market is estimated to reach US$759.61 billion in 2025, progressing at a CAGR of 10.95%, over the period 2021-2025. Factors such as increasing geriatric population, upsurge in demand for convenient drug delivery, expanding use of biologics, rising healthcare expenditure and surging incidence of cancer cases would drive...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to grow from $0.76 billion in 2020 to $0.87...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the coronavirus (COVID-19) current therapy market are Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., Biocryst Pharma, Gilead Sciences, and Regeneron Pharmaceuticals. The global coronavirus (COVID-19) current therapy market is expected to...
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 18.104.22.168) - Drugs in Development, 2021 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 22.214.171.124) - Protein kinase C (PKC) is an enzyme belonging to a family of serine- and threonine-specific protein kinases that is activated...
High Net Worth Individuals Number
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.